Welcome to our dedicated page for Johnson & Johnson news (Ticker: JNJ), a resource for investors and traders seeking the latest updates and insights on Johnson & Johnson stock.
Johnson & Johnson reports healthcare developments across its Innovative Medicine and MedTech businesses. News commonly covers clinical and scientific data in immunology, oncology, neurology and neuropsychiatry, including medicines and candidates such as CAPLYTA, TREMFYA, JNJ-4804, seltorexant and the INVEGA long-acting injectable schizophrenia portfolio.
Company updates also include medical technology programs such as the investigational OTTAVA robotic surgical system, product and patient-education initiatives, quarterly sales and earnings releases, dividend actions, investor presentations and governance or investor-relations appointments.
Johnson & Johnson (NYSE: JNJ) announced the FDA granted Priority Review to the supplemental BLA for IMAAVY (nipocalimab-aahu) for warm autoimmune hemolytic anemia (wAIHA), shortening the U.S. review timeline to approximately six months.
The Priority Review is supported by the Phase 2/3 ENERGY study, in which IMAAVY achieved a durable hemoglobin response and improved fatigue versus placebo; full ENERGY results will be presented at an upcoming medical conference. IMAAVY is not yet approved for wAIHA.
Johnson & Johnson (NYSE: JNJ) reported long-term results for IMAAVY (nipocalimab-aahu) in antibody-positive adults with generalized myasthenia gravis, extending follow-up to 120 weeks. Key findings include sustained symptom improvements, mean MG-ADL reduction of 6.47 points, QMG reduction of 5.97, and durable IgG lowering.
Half of patients reached minimal symptom expression and 32% sustained it for at least 8 weeks; corticosteroid use fell with 57% at low doses. EPIC, a head-to-head study versus efgartigimod, is now enrolling.
Johnson & Johnson (NYSE: JNJ) will participate in the 2026 RBC Capital Markets Global Healthcare Conference on Tuesday, May 19, 2026.
Management will hold a Fireside Chat at 11:30 a.m. ET. A live audio webcast will be available to investors at www.investor.jnj.com, with an audio replay posted approximately 48 hours after the event.
Johnson & Johnson (NYSE: JNJ) will showcase CARTO innovations at HRS 2026, marking 30 years of the CARTO System and launching the CARTOSOUND SONATA AI module to convert intracardiac echocardiography into detailed maps and auto-label cardiac structures.
The company will present 17 abstracts, new VARIPULSE Platform data, and hands-on demos April 24–2026, highlighting PFA advances and workflow updates across electrophysiology.
Johnson & Johnson (NYSE: JNJ) will present at the Bank of America 2026 Healthcare Conference on Tuesday, May 12, 2026. Management will join a Fireside Chat at 2:20 p.m. ET.
A live audio webcast will be available via Johnson & Johnson’s Investor Relations website with an archived edition available later that day and an audio replay about 48 hours after the webcast.
Johnson & Johnson (NYSE: JNJ) declared a 3.1% quarterly dividend increase, raising the payout from $1.30 to $1.34 per share and marking the 64th consecutive year of annual increases. The new indicated annual dividend is $5.36 versus $5.20 previously.
The next quarterly dividend is payable on June 9, 2026 to shareholders of record at the close of business on May 26, 2026; the ex-dividend date is May 26, 2026.
Johnson & Johnson (NYSE: JNJ) reported Q1 2026 reported sales of $24.1 billion, up 9.9%, with adjusted Q1 EPS of $2.70 and GAAP diluted EPS of $2.14. The company raised 2026 guidance to estimated reported sales of $100.8 billion (midpoint, +7.0%) and adjusted EPS midpoint of $11.55 (+7.1%).
The quarter included multiple regulatory approvals and launches (ICOTYDE, TECNIS PureSee, TECVAYLI plus DARZALEX FASPRO, VARIPULSE Pro) and an estimated Q1 free cash flow of about $1.5 billion. An Enterprise Business Review is planned for December 8, 2026.
Johnson & Johnson (NYSE: JNJ) presented clinical data April 10, 2026 for the FDA-approved TECNIS PureSee IOL at ASCRS showing strong distance and intermediate vision, high spectacle independence for distance/intermediate, and low bothersome visual symptoms across U.S., Europe and Asia Pacific studies.
Key metrics: a 293-patient real-world study and a 200-patient randomized U.S. trial reported mean binocular uncorrected distance vision ~20/19, spectacle independence up to 96% for distance, and patient satisfaction rates of 93–97%.
Johnson & Johnson (NYSE: JNJ) launched VARIPULSE Pro in Europe after CE Mark approval on April 7, 2026, advancing its pulsed field ablation portfolio.
VARIPULSE Pro features a new pulse sequence with a lower temperature profile, claims 5x faster ablation versus the prior sequence while achieving equivalent lesions, and integrates with the CARTO 3 System. Twelve-month interim VARIPURE study data will be presented at EHRA 2026. VARIPULSE Pro is not approved in the United States.
Johnson & Johnson (NYSE: JNJ) reported 52-week Phase 3 results for ICOTYDE (icotrokinra) in moderate-to-severe plaque psoriasis showing sustained skin clearance and a favorable safety profile.
ADVANCE 1 PASI100 rose from 41% to 49%, ADVANCE 2 from 33% to 48%; adolescents reached 57% PASI100 and 61% IGA 0 at Week 52. No new safety signals were identified.